X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will support Company’s research and development strategy, with investigational new drug application filings for ZW171 and ZW191. ZW171 is a bispecific antibody that is designed to engage two different types of cells, tumor cells and immune cells.
Lead Product(s): ZW171
Therapeutic Area: Oncology Product Name: ZW171
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 26, 2023
Details:
Zymeworks and Daiichi Sankyo entered into the Collaboration Agreement to research, develop and commercialize one bispecific antibody generated through the use of Zymeworks BC’s Azymetric and EFECT platforms.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: $484.7 million Upfront Cash: $18.0 million
Deal Type: Termination March 20, 2023
Details:
ZW25 (zanidatamab) is an investigational bispecific antibody, based on Zymeworks' Azymetric™ platform, that simultaneously bind two non-overlapping epitopes of HER2, which encourages antitumor activity in patients. It is being investigated for solid tumors that express HER2.
Lead Product(s): Zanidatamab,Capecitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Jazz Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
ZW25 (zanidatamab) is an investigational bispecific antibody, based on Zymeworks' Azymetric™ platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding.
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $1,762.5 million Upfront Cash: $50.0 million
Deal Type: Collaboration December 21, 2022
Details:
Zanidatamab (ZW25) as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC).
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
Zanidatamab is a novel HER2-targeted bispecific antibody with biparatopic binding and the potential to transform the current standard of care in multiple HER2 expressing cancers.
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
ZW49 (zanidatamab) is bispecific antibody, based on Zymeworks’ Azymetric™ platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding.
Lead Product(s): Zanidatamab,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: ZW49
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
Jazz to obtain exclusive development and commercialization rights of ZW25 (Zanidatamab) in the U.S., Europe and Japan to expand oncology portfolio. Zanidatamab is HER2-targeted bispecific antibody demonstrated anti-tumor activity in HER2-expressing cancers.
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $1,762.5 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement October 19, 2022
Details:
Zanidatamab zovodotin (ZW49), is a novel bispecific HER2 ‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin.
Lead Product(s): Zanidatamab Zovodotin
Therapeutic Area: Oncology Product Name: ZW49
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
ZW49 (zanidatamab zovodotin) shown to have manageable safety profile with encouraging, single-agent anti-tumor activity in patients with HER2+ cancers.
Lead Product(s): Zanidatamab Zovodotin
Therapeutic Area: Oncology Product Name: ZW49
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
